10 Best Multibagger Stocks To Buy Heading into 2025

7. Delcath Systems, Inc. (NASDAQ:DCTH)

1-Year Share Price Performance: ~226%

2-Year Share Price Performance: ~224%

Average Price Target Upside: 122.45%

Delcath Systems, Inc. (NASDAQ:DCTH) specializes in interventional oncology, focusing on treating liver cancers, including those that are primary or metastatic. Its key products are the HEPZATO KIT and CHEMOSAT Hepatic Delivery System, both designed to deliver high-dose chemotherapy to the liver while managing systemic exposure during percutaneous hepatic perfusion (PHP) procedures.

In the U.S., the HEPZATO KIT, a drug-device combination regulated by the FDA, includes the chemotherapy drug melphalan and Delcath’s Hepatic Delivery System (HDS). The HDS isolates liver blood flow from the systemic circulation and filters it during treatment, enabling high-dose, targeted therapy with reduced risk of systemic side effects and liver toxicity.

The treatment is approved for adults with metastatic uveal melanoma affecting the liver under specific conditions. In Europe, Delcath offers the HDS as the CHEMOSAT system, a Class III medical device approved for PHP procedures at medical centers treating several liver cancers.

In the third quarter, Delcath (NASDAQ:DCTH) achieved $11.2 million in revenue, marking a 44% increase from the prior quarter. This included $10 million in U.S. sales from HEPZATO KIT and $1.2 million from European sales of CHEMOSAT. With 12 active HEPZATO treatment centers in the U.S., the company aims to have 15 by year-end and reach 30 by the end of 2025. Additionally, a $10 million revenue milestone triggered a $25 million funding influx from exercised warrants.

In Europe, CHEMOSAT revenue grew 100% year-over-year, though it remained stable compared to the prior quarter. The company is expanding CHEMOSAT’s presence in France, Italy, and Spain to support research and trials.

Furthermore, Delcath’s (NASDAQ:DCTH) gross margin reached 85% for the quarter. R&D expenses declined to $3.9 million from $4.6 million due to lower access program costs, while SG&A costs rose to $7 million due to commercial launch activities. With $14 million in cash, no outstanding debt, and recent warrant exercises adding $25 million, the company anticipates achieving profitability while funding further clinical trials.